(NASDAQ:AMAT), Record annual revenue $28.37 billion, up 4 percent year over year Record annual GAAP EPS $8.66 and record non-GAAP EPS $9.42, up 1 percent and 9 percent year over year, respectively Quarterly revenue $6.80 billion, down 3 percent year over year Quarterly GAAP EPS $2.38 and non-GAAP EPS $2.17, up 14 percent and down […]
(NASDAQ:RLMD), Positive 9-month follow-up data for NDV-01 showed a 92% overall response rate at any time in non-muscle invasive bladder cancer (NMIBC), with favorable overall safety Secured FDA alignment on key elements of Phase 3 program with two independent paths for approval in two separate NMIBC indications: High-risk 2nd line BCG-unresponsive, and Intermediate-risk patients in
(TSX:FRU), CALGARY, Alberta, Nov. 13, 2025 (GLOBE NEWSWIRE) — Freehold Royalties Ltd. (Freehold or the Company) (TSX:FRU) announces third quarter results for the period ended September 30, 2025. Third Quarter Highlights $74 million in revenue; $59 million in funds from operations ($0.36/share) (1)(2); $44 million in dividends paid ($0.27/share)(3); 16,054 boe/d(4) of total production, a
(NasdaqGM:TELA), MALVERN, Pa., Nov. 13, 2025 (GLOBE NEWSWIRE) — TELA Bio, Inc. (“TELA Bio”), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Financial Highlights Revenue of $20.7 million, a 9% increase from the third quarter of
(NASDAQ:ELTX), In the ongoing Phase 2 AMPLIFY-7P study evaluating ELI-002 7P in patients with pancreatic ductal adenocarcinoma (“PDAC”), fewer disease progressions and deaths than projected have been observed as of November 6, 2025. Based on 2:1 randomization with twice as many patients in the ELI-002 7P treatment arm compared to the observation arm, Elicio believes
(NASDAQ:BNGO), SAN DIEGO, Nov. 13, 2025 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the third quarter ended September 30, 2025. “Over the last year, we have taken decisive steps to transform our business model by focusing on driving consumables and software utilization among our existing routine use customers. We
(TSX:FRX),(NASDAQ:FENC), ~ Q3 2025 Total Net Product Sales of $12.5 Million, 79% Year Over Year Growth ~ ~ Q3 2025 Positive Cash Flow from Operations, Cash Position Grew to $22 Million ~ ~ Japan Clinical Trial (STS-J01) Preliminary Results Expected in Q4 2025 ~ RESEARCH TRIANGLE PARK, N.C., Nov. 13, 2025 (GLOBE NEWSWIRE) — Fennec
(NASDAQ:AMRX), BRIDGEWATER, N.J., Nov. 13, 2025 (GLOBE NEWSWIRE) — Amneal Pharmaceuticals, Inc. (“Amneal” or the “Company”) (Nasdaq: AMRX) today announced the U.S. Food and Drug Administration (FDA) has approved the Company's iohexol injection (300 mg Iodine/mL), the first generic version of GE Healthcare's Omnipaque(R) (iohexol) injection. Amneal expects to launch the product in the first
(NASDAQ:DARE), DARE to PLAY(TM) Sildenafil Cream on Track to Launch Before Year End via 503B Pathway, Paving the Way for Near-Term Product Revenue Positive Interim DSMB Outcome for Ovaprene(R) Phase 3 Study Supports Continued Enrollment Multiple Grant-Funded Programs Advance, Including to Address HPV and Long-Acting as well as Non-Hormonal Contraception Four Commercially Available Solutions for
(NASDAQ:NCNA), Announced Encouraging Data on both NUC-7738 and NUC-3373 Initial Data from the Expansion Study of NUC-7738 Expected in Q4 2025 with Final Data Expected in 2026 Compliant with All Nasdaq Continued Listing Criteria Well Capitalized with Anticipated Cash Runway into 2029 EDINBURGH, United Kingdom, Nov. 13, 2025 (GLOBE NEWSWIRE) — NuCana plc (NASDAQ: NCNA)